Compare Citius Pharmaceuticals Inc (CTXR) vs Five Below Inc (FIVE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs Five Below Inc — how do they compare? Citius Pharmaceuticals Inc trades at $0.54 (market cap $14.64M), while Five Below Inc trades at $194.82 (market cap $10.68B). The key difference: Five Below Inc is far larger — about 729.5× Citius Pharmaceuticals Inc's market cap, and Five Below Inc is trading nearer its 52-week high, Citius Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| CTXR | FIVE | |
|---|---|---|
Market Cap | $14.64M | $10.68B |
Sector | Health | Consumer Staples |
52-Week High | $1.82 | $247.71 |
52-Week Low | $0.53 | $131.94 |
Enterprise Value | $10.86M | $11.56B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.54, down 7.33% in the last session, with a bearish technical signal from moving averages. The company reported a net loss of $37.43M for 2025 and has missed earnings expectations for the last three quarters. Recent news highlights progress with LYMPHIR, including Phase 1 data presentations at ASCO and international expansion, alongside $5.6M in net revenue for the first half of 2026.
Despite a high analyst buy consensus (83%), CTXR faces significant fundamental challenges with negative profitability and cash burn. Investment opportunity hinges on successful commercialization of LYMPHIR, but risks include ongoing losses, dilution from recent financing, and clinical execution uncertainties. The stock remains speculative with high risk-reward dynamics.
Five Below (FIVE) trades at $191.53, up 1.13% on the day, with a bullish technical signal and consistent earnings beats. The stock shows strong profitability with a 21.13% ROE and 8.67% net margin, supported by revenue growth from $3.6B in 2024 to $3.9B in 2025. Recent milestones include opening its 2,000th store and leadership appointments, driving positive media coverage.
The outlook remains positive with a $252.09 analyst price target implying 31% upside, though risks include volatile cash flows and competitive pressures. Earnings momentum and digital marketing investments position FIVE for growth, but investors should monitor execution against 2026's $5.1B revenue target.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About Five Below Inc
Five Below is a value-oriented retailer that operated 1,190 stores in the United States as of the end of fiscal 2021. Catering to teen and preteen consumers, stores feature a wide variety of merchandise, the vast majority of which is priced below $6. The assortment focuses on discretionary items in several categories, particularly leisure (such as sporting goods, toys, and electronics
Read more on FIVE →
